Calvary Mater Newcastle Hospital

Waratah NSW 2298

2 studies enrolling now · 10 studies all time

What they study most

Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN), Estrogen Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, MF, Multiple Myeloma, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis

Studies at this site

• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma — Recruiting now
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma — Running, not enrolling
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Running, not enrolling
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy — Running, not enrolling
• A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma — Completed
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma — Running, not enrolling
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer — Running, not enrolling
• A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma — Completed
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) — Stopped early